|
Study | Year | Design | Analyzed patients (intervention/ placebo) | Intervention | Daily Dose | Baseline pain score (mm) | End of Rx pain score (mm) | Pain outcome measure | Mean SE reduction from baseline with active treatment (mm) (95% CI) | Mean SE reduction from baseline with placebo (mm) (95% CI) | Mean Difference SE in pain scores between groups (mm) (95% CI) Effect Size |
|
Eberhardt et al. [56] | 1995 | Single centre Double blind placebo controlled parallel | DMSO: 56 Placebo: 56 | DMSO | 25% DMSO gel/day 5–8 cm | DMSO = 64.3 Placebo = 64.1 | DMSO = 21.6 Placebo = 33.3 | Pain VAS (0–100 mm) | 42.7 2.34 [] | 30.8 2.38 [] | 11.7 3.31 [] Effect = 3.53 |
Bookman et al. [36] | 2004 | Multi centre, Double blind, three arma comparative parallel arm | DMSO: 79 Placebo: 84 | DMSO | 45.5% wt/wt | DMSO = 46.5 Placebo = 47.0 | DMSO = 34.0 Placebo = 34.5 | WOMAC pain subscale (0–20 m) (scaled up to 100 mm for comparison) | 12.5 2.7 [] | 12.5 2.0 [] | 0.0 3.35 [] Effect = 0.00 |
Kim et al. [43] | 2006 | Single centre, double blind placebo controlled parallel arm | MSM: 21 Placebo: 19 | MSM | 3 g/day oral | MSM = 58.0 Placebo = 55.1 | MSM = 43.4 Placebo = 47.9 | WOMAC pain subscale (0–100 mm) | 14.6 1.3 [] | 7.3 3.3 [] | 7.3 3.55 [] Effect = 2.06 |
| | | | | | | | | | | 6.34 1.96 [2.41, 10.27] |
| Meta-analyses (fixed effects) | 6.34 3.49 [] |
| Meta-analysis (random effects) | |
|